NASDAQ:ATNX

Athenex Stock Forecast, Price & News

$3.34
-0.16 (-4.57 %)
(As of 09/20/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.28
$3.50
50-Day Range
$3.18
$4.13
52-Week Range
$3.12
$15.00
Volume1.15 million shs
Average Volume3.35 million shs
Market Capitalization$365.09 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
30 days | 90 days | 365 days | Advanced Chart
Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.


Athenex logo

About Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

244th out of 1,352 stocks

Pharmaceutical Preparations Industry

117th out of 665 stocks

Analyst Opinion: 3.2Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Athenex (NASDAQ:ATNX) Frequently Asked Questions

Is Athenex a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Athenex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATNX, but not buy additional shares or sell existing shares.
View analyst ratings for Athenex
or view top-rated stocks.

What stocks does MarketBeat like better than Athenex?

Wall Street analysts have given Athenex a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athenex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Athenex's next earnings date?

Athenex is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Athenex
.

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) announced its earnings results on Wednesday, August, 4th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.04. The company had revenue of $21.92 million for the quarter, compared to analysts' expectations of $22.07 million. Athenex had a negative trailing twelve-month return on equity of 84.67% and a negative net margin of 121.58%.
View Athenex's earnings history
.

How has Athenex's stock price been impacted by Coronavirus (COVID-19)?

Athenex's stock was trading at $9.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATNX shares have decreased by 65.4% and is now trading at $3.34.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ATNX?

9 brokerages have issued twelve-month target prices for Athenex's stock. Their forecasts range from $4.00 to $27.00. On average, they expect Athenex's share price to reach $10.14 in the next year. This suggests a possible upside of 203.7% from the stock's current price.
View analysts' price targets for Athenex
or view top-rated stocks among Wall Street analysts.

Who are Athenex's key executives?

Athenex's management team includes the following people:
  • Yiu Nam Lau, Chairman & Chief Executive Officer
  • Jeffrey M. Yordon, COO & President-Athenex Pharmaceutical Division
  • Steven Adams, Controller, Chief Financial & Accounting Officer
  • Rudolf Kwan, Chief Medical Officer
  • Teresa Bair, Secretary, SVP-Administration & General Counsel

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

(ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

Who are Athenex's major shareholders?

Athenex's stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (7.85%), BlackRock Inc. (6.16%), Vanguard Group Inc. (3.89%), Morgan Stanley (1.92%), Morgan Stanley (1.92%) and Millennium Management LLC (1.52%). Company insiders that own Athenex stock include Benson Kwan Hung Tsang, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, Rudolf Kwan and William Wei Zuo.
View institutional ownership trends for Athenex
.

Which major investors are selling Athenex stock?

ATNX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, National Asset Management Inc., Ingalls & Snyder LLC, Susquehanna International Group LLP, Occudo Quantitative Strategies LP, Nuveen Asset Management LLC, Rafferty Asset Management LLC, and Bank of America Corp DE.
View insider buying and selling activity for Athenex
or view top insider-selling stocks.

Which major investors are buying Athenex stock?

ATNX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Millennium Management LLC, BlackRock Inc., Ikarian Capital LLC, Geode Capital Management LLC, Credit Suisse AG, and Dupont Capital Management Corp. Company insiders that have bought Athenex stock in the last two years include Benson Kwan Hung Tsang, Jinn Wu, Johnson Yiu Nam Lau, Jordan Kanfer, Kim Campbell, Life Sciences Maste Perceptive, Manson Fok, Perceptive Advisors Llc, Randoll Sze, and Rudolf Kwan.
View insider buying and selling activity for Athenex
or or view top insider-buying stocks.

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $3.34.

How much money does Athenex make?

Athenex has a market capitalization of $365.09 million and generates $144.39 million in revenue each year. The company earns $-146,180,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis.

How many employees does Athenex have?

Athenex employs 599 workers across the globe.

What is Athenex's official website?

The official website for Athenex is www.athenex.com.

Where are Athenex's headquarters?

Athenex is headquartered at 1001 Main Street Suite 600, Buffalo NY, 14203.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at (716) 427-2950 or via email at [email protected].


This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.